Capped analogue and application thereof
By transcribing and synthesizing capped analogs of mRNA in vitro, the problem of in vitro transcription and synthesizing mRNA triggering an immune response was solved. By combining with RNA polymerase with specific capped structures, inhibitory capped mRNA was generated, which significantly reduced RIG-I and The binding of IFIT1 achieves effective blockade of the immune response.
Patent Information
- Application Number
- CN202411058327.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2021-08-27
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to effectively inhibit the immune response triggered by in vitro transcription and synthesis of mRNAs, especially because the lack of 2’-O-methylation of exogenous mRNAs are recognized by IFIT1 and prevented transcription.
A new class of capping analogs was developed to synthesize mRNA through in vitro transcription, and use specific capping structures (such as m7GpppApG, m7GpppA2'Ome pG, etc.) to bind with RNA polymerase and nucleoside triphosphate in in vitro transcription reaction to generate It has inhibitory capping mRNA, thereby reducing binding to RIG-I and IFIT1 and blocking the immune response.
It effectively inhibits the occurrence of immune response, improves the stability and translation efficiency of mRNA, significantly reduces the binding ability to RIG-I and IFIT1, and achieves stricter blockade of immune response.
Smart Images

Figure CN118978560A_ABST
Abstract
Description
[0001] This patent application is a divisional application of the invention patent application with application number CN 202110995875.X. Technical Field
[0002] The present invention relates to the fields of chemistry and bioengineering; more specifically, to a series of capping analogs for synthesizing mRNA by in vitro transcription (IVT) and the application of the capping analogs in mRNA synthesis. Background Art
[0003] Synthesizing mRNA through in vitro transcription has become an important tool for introducing foreign genes and expressing proteins, and is widely used in the treatment and prevention of diseases. The immune response induced by foreign mRNA will affect the expression of target proteins through different pathways.
[0004] N1-2'O-methylation is important for blocking RIG-I activation, and knockout of intracellular N1-2'O-methyltransferase also causes immune stimulation of endogenous RNA. 7 G cap synergistically reduces the binding affinity of RNA to RIG-I.
[0005] During mRNA transcription, IFIT1 and the translation factor EIF4E can compete for binding to the mRNA template. Endogenous and exogenous mRNAs with cap structures and 2'-O-methylation are bound by EIF4E to initiate transcription. However, if the exogenous mRNA lacks 2'-O-methylation on the first ribose, it will be recognized by IFIT1, thereby preventing the binding of intracellular factors and hindering transcription. However, N1 methylation alone may not be sufficient to protect all endogenous mRNAs from the influence of IFIT1. IFIT1's recognition of 2'-O methylation on N1 and N2 riboses shows that the methyl group conflicts with these protein residues.
[0006] Therefore, there is an urgent need in the art to develop a new class of capping analogs so that the mRNA synthesized by in vitro transcription can effectively inhibit the occurrence of immune response. Summary of the invention
[0007] The purpose of the present invention is to provide a new type of capped analogs with a general structural formula as shown in (I) and their application.
[0008] In the first aspect of the present invention, a capped analogue represented by formula (I) is provided:
[0009]
[0010]
[0011] Wherein, B1 and B2 are natural or modified bases, respectively;
[0012] E and F are 0 or 1 respectively;
[0013] R1 is H, OH, alkyl, O-alkyl, halogen, or oxygen and the oxygen forms a bridged ring with the C at the 3' and 5' positions;
[0014] R2 is H, OH, alkyl, O-alkyl or halogen;
[0015] R3 is O-R5-R6;
[0016] R4 is hydrogen, hydroxy, O-methyl or O-R5-R6;
[0017] R5 is substituted or unsubstituted C 1-20 alkyl;
[0018] R6 is substituted or unsubstituted O-alkyl, substituted or unsubstituted S-alkyl, substituted or unsubstituted NH-alkyl, substituted or unsubstituted N-dialkyl, substituted or unsubstituted O-aryl, substituted or unsubstituted S-aryl, substituted or unsubstituted NH-aryl, substituted or unsubstituted O-aralkyl, substituted or unsubstituted S-aralkyl, substituted or unsubstituted NH-aralkyl, or hydrogen (R5 is substituted or unsubstituted C 2-20 alkyl);
[0019] X1, X2 and X3 are O, CH2 or NH respectively;
[0020] Y1, Y2 and Y3 are O, S, Se, or BH3 respectively.
[0021] In another embodiment, R3 is OCH2CH3, OCH2OCH3 or OCH2CH2OCH3.
[0022] In another embodiment, R4 is hydroxy, OCH2CH3, OCH2OCH3 or OCH2CH2OCH3.
[0023] In another embodiment, B1 and B2 are each adenine, N6-methyladenine, guanine, uracil, or thymine.
[0024] In another embodiment, the capping analog is selected from: m7 GpppA 2’O-ethyl pG, m7 GpppA 2’O-ethyl pA, m7 GpppA 2’O-ethyl pC, m7 GpppA 2’O-ethyl pU m7 Gppp 2’O-ethyl pA, m7Gppp 2’O-ethyl pG, m7 Gppp 2’O-ethyl pC, m7 Gppp 2’O-ethyl pU m7 GpppG 2’O-ethyl pA, m7 GpppG 2’O-ethyl pC, m7 GpppG 2’O-ethyl pG, m7 GpppG 2’O- ethyl pU m7 GpppU 2’O-ethyl pA, m7 GpppU 2’O-ethyl pC, m7 GpppU 2’O-ethyl pC, or m7 GpppU 2’O-ethyl pU.
[0025] In another embodiment, the capping analog is selected from: m7 G 3’Ome pppA 2’O-ethyl pG, m7 G 3’Ome pppA 2’O-ethyl pA, m7 G 3’Ome pppA 2’O-ethyl pC, m7 G 3’Ome pppA 2’O-ethyl pU m7 G 3’Ome pppC 2’O-ethyl pA, m7 G 3’ Ome pppC 2’O-ethyl pG, m7 G 3’Ome pppC 2’O-ethyl pC, m7 G 3’Ome pppC 2’O-ethyl pU m7 G 3’Ome pppG 2’O-ethyl pA, m7 G 3’ Ome pppG 2’O-ethyl pC, m7 G 3’Ome pppG 2’O-ethyl pG, m7 G 3’Ome pppG2’O-ethyl pU m7 G 3’Ome U 2’O-ethyl pA, m7 G 3’ Ome U 2’O-ethyl pC, m7 G 3’Ome U 2’O-ethyl pC, or m7 G 3’Ome U 2’O-ethyl pU.
[0026] In another embodiment, the capping analog is selected from: m7 G 2’Ome pppA 2’O-ethyl pG, m7 G 2’ Ome pppA 2’O-ethyl pA, m7 G 2’Ome pppA 2’O-ethyl pC, m7 G 2’Ome pppA 2’O-ethyl pU m7 G 2’Ome pppC 2’O-ethyl pA, m7 G 2’ Ome pppC 2’O-ethyl pG, m7 G 2’Ome pppC 2’O-ethyl pC, m7 G 2’Ome pppC 2’O-ethyl pU m7 G 2’Ome pppG 2’O - ethyl pA, m7 G 2’ Ome pppG 2’O-ethyl pC, m7 G 2’Ome pppG 2’O-ethyl pG, m7 G 2’Ome pppG 2’O-ethyl pU m7 G 2’Ome U 2’O-ethyl pA, m7 G 2’ Ome U 2’O-ethyl pC, m7 G2’Ome U 2’O-ethyl pC, or m7 G 2’Ome U 2’O-ethyl pU.
[0027] In another embodiment, the capping analog is selected from: m7 Gppp (N6-methyladenine) 2’O-ethyl pG, m7 Gppp (N6-methyladenine) 2’O-ethyl pA, m7 Gppp (N6-methyladenine) 2’O-ethyl pC, m7 Gppp (N6-methyladenine) 2’O-ethyl pU m7 G 2’Ome ppp(N6-methyladenine) 2’O-ethyl pA, m7 G 2’Ome ppp(N6-methyladenine) 2’O-ethyl pG, m7 G 2’Ome ppp(N6-methyladenine) 2’O-ethyl pC, m7 G 2’Ome ppp(N6-methyladenine) 2’O-ethyl pU m7 G 3’Ome ppp(N6-methyladenine) 2’O-ethyl pA, m7 G 3’Ome ppp(N6-methyladenine) 2’O-ethyl pC, m7 G 3’Ome ppp(N6-methyladenine) 2’O-ethyl pC, or m7 G 3’Ome ppp(N6-methyladenine) 2’O-ethyl pU.
[0028] In another embodiment, the capping analog is selected from: m7 GpppA 2’O-MOE pG, m7 GpppA 2’O-MOE pA, m7 GpppA 2’O-MOE pC, m7 GpppA 2’O-MOE pU m7 Gppp 2’O-MOE pA, m7 Gppp 2’O-MOE pG,m7 Gppp 2’O-MOE pC, m7 Gppp 2’O-MOE pU m7 GpppG 2’O-MOE pA, m7 GpppG 2’O-MOE pC, m7 GpppG 2’O-MOE pG, m7 GpppG 2’O-MOE pU m7 GpppU 2’O-MOE pA, m7 GpppU 2’O-MOE pC, m7 GpppU 2’O-MOE pC, or m7 GpppU 2’O-MOE pU.
[0029] In another embodiment, the capping analog is selected from: m7 G 3’Ome pppA 2’O-MOE pG, m7 G 3’Ome pppA 2’O- MOE pA, m7 G 3’Ome pppA 2’O-MOE pC, m7 G 3’Ome pppA 2’O-MOE pU m7 G 3’Ome pppC 2’O-MOE pA, m7 G 3’Ome pppC 2’O-MOE pG, m7 G 3’Ome pppC 2’O-MOE pC, m7 G 3’Ome pppC 2’O-MOE pU m7 G 3’Ome pppG 2O-’MOE pA, m7 G 3’Ome pppG 2’O-MOE pC, m7 G 3’ Ome pppG 2’O-MOE pG, m7 G 3’Ome pppG 2’O-MOE pU m7 G 3’OmeU 2’O-MOE pA, m7 G 3’Ome U 2’O-MOE pC, m7 G 3’ Ome U 2’O-MOE pC, or m7 G 3’Ome U 2’O-MOE pU.
[0030] In another embodiment, the capping analog is selected from: m7 G 2’Ome pppA 2’O-MOE pG, m7 G 2’Ome pppA 2’O- MOE pA, m7 G 2’Ome pppA 2’O-MOE pC, m7 G 2’Ome pppA 2’O-MOE pU m7 G 2’Ome pppC 2’O-MOE pA, m7 G 2’Ome pppC 2’O-MOE pG, m7 G 2’Ome pppC 2’O-MOE pC, m7 G 2’Ome pppC 2’O-MOE pU m7 G 2’Ome pppG 2’O-MOE pA, m7 G 2’Ome pppG 2’O-MOE pC, m7 G 2’ Ome pppG 2’O-MOE pG, m7 G 2’Ome pppG 2’O-MOE pU m7 G 2’Ome U 2’O-MOE pA, m7 G 2’Ome U 2’O-MOE pC, m7 G 2’ Ome U 2’O-MOE pC, or m7 G 2’Ome U2’O-MOE pU.
[0031] In another embodiment, the capping analog is selected from: m7 Gppp (N6-methyladenine) 2’O-MOE pG, m7 Gppp (N6-methyladenine) 2’O-MOE pA, m7 Gppp (N6-methyladenine) 2’O-MOE pC, m7 Gppp (N6-methyladenine) 2’O- MOE pU m7 G 2’Ome ppp(N6-methyladenine) 2’O-MOE pA, m7 G 2’Ome ppp(N6-methyladenine) 2’O-MOE pG, m7 G 2’Ome ppp(N6-methyladenine) 2’O-MOE pC, m7 G 2’Ome ppp(N6-methyladenine) 2’O-MOE pU m7 G 3’Ome ppp(N6-methyladenine) 2’O-MOE pA, m7 G 3’Ome ppp(N6-methyladenine) 2’O-MOE pC, m7 G 3’Ome ppp(N6-methyladenine) 2’O-MOE pC, or m7 G 3’Ome ppp(N6-methyladenine) 2’O-MOE pU.
[0032] In another embodiment, the structure of the capped analog is shown in Formula (Ia) or Formula (Ib):
[0033]
[0034] Wherein, B1 and B2 are natural or modified bases, respectively;
[0035] R3 is O-R5-R6.
[0036] In another embodiment, R3 is OCH2CH3, OCH2OCH3 or OCH2CH2OCH3.
[0037] In another embodiment, B1 and B2 are each adenine, N6-methyladenine, guanine, uracil, or thymine.
[0038] In a second aspect of the present invention, a polynucleotide encoding a target polypeptide is provided, the polynucleotide comprising:
[0039] (a) at least one ORF region;
[0040] (b) a 5'UTR with at least one Kozak sequence;
[0041] (c) 3'UTR; and
[0042] (d) at least one 5'-initial capped capping analog provided by the present invention as described above.
[0043] In the third aspect of the present invention, a pharmaceutical composition is provided, wherein the pharmaceutical composition contains the polynucleotide provided by the present invention as described above and a pharmaceutically acceptable carrier.
[0044] In another embodiment, the carrier is selected from lipid nanoparticles (LNPs), liposomes, polymeric nanoparticles, solid lipid nanoparticles or emulsions.
[0045] In a fourth aspect of the present invention, a method for preparing the polynucleotide provided by the present invention as described above is provided, the method comprising the steps of:
[0046] (1) preparing a DNA template;
[0047] (2) performing an in vitro transcription reaction to obtain the polynucleotide provided by the present invention as described above, wherein the reaction system contains RNA polymerase, nucleoside triphosphates and the capping analog provided by the present invention as described above.
[0048] In another embodiment, the nucleoside triphosphate can be a natural base nucleoside triphosphate, a modified nucleoside triphosphate or a non-natural nucleoside triphosphate; preferably ATP, CTP, GTP, UTP, 5me-CTP, 5me-UTP, PseudoUTP or N1-me-PseudoUTP.
[0049] In another embodiment, the RNA polymerase is an RNA polymerase derived from a bacteriophage.
[0050] In another embodiment, the RNA polymerase is selected from T7, SP6, or T3.
[0051] In another embodiment, the RNA polymerase can be a mutant of RNA polymerase derived from bacteriophage, with at least 80%, 90%, 95%, 96%, 97%, 98%, 99% of the amino acid sequence being identical to the natural sequence.
[0052] Accordingly, the present invention provides a new class of capping analogs, so that the mRNA synthesized by in vitro transcription can effectively inhibit the occurrence of immune response. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1-3 The synthetic route for the capped analog in Example 1 is shown.
[0054] Figure 4 The protein expression of different capped analog mRNAs obtained in the examples is shown.
[0055] Figure 5 The relative binding abilities of different capped analog mRNAs obtained in the examples to RIG-I are shown.
[0056] Figure 6 The relative binding abilities of different capped analog mRNAs obtained in the examples to IFIT1 are shown.
[0057] Figure 7 The results of the determination of immunogenicity induced by different capped analog mRNAs obtained in the Examples are shown.
[0058] Figure 8 The capped analogs obtained in the examples are shown m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L- LNA pppA 2’O-ethyl Protein expression of pG mRNA.
[0059] Fig. 9 Different capped analogs obtained by showing the examples m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L- LNA pppA 2’O-ethyl Relative binding ability of pG mRNA to RIG-I.
[0060] Fig.10 Different capped analogs obtained by showing the examples m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L- LNApppA 2’O-ethyl Relative binding ability of pG mRNA to IFIT1.
[0061] Fig.11 Different capped analogs obtained by showing the examples m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L- LNA pppA 2’O-ethyl Results of the assay of pG mRNA-induced immunogenicity.
[0062] Fig.12 The capping efficiency HPLC graph of different capping nucleotides obtained in the embodiment is shown; wherein,
[0063] A is m7 GpppApG, B is m7 G pppA 2’Ome pG, C is m7 G 3’Ome pppA 2’O-ethyl pG, D is m7 G 2’ Ome pppA 2’O-ethyl pG, E is m7 G 3’Ome pppA 2’O-MOE pG, F is m7 G 2’Ome pppA 2’O-MOE pG, G is m7 Gppp(N6-methyladenine) 2’O-MOE pG), H is m7 G 2’Ome pppC 2’O-ethyl pC, I is m7 G 3’Ome pppA 2’O-MOE pU's.
[0064] Fig.13 The capping efficiency HPLC graph of different capping nucleotides obtained in the embodiment is shown; wherein,
[0065] A is m7 GpppApG, B is m7 G pppA 2’Ome pG (control), C is m7 G Beta-D-LNA pppA 2’O-MOE pG, D is m7 G Alpha-L-LNA pppA 2’O-ethylpG. DETAILED DESCRIPTION
[0066] After extensive and in-depth research, the inventors synthesized and screened a series of tri-oligonucleic acid polymers and found for the first time that the mRNA obtained by IVT using the capped analog of formula (I) greatly hindered its binding to IFIT1 and also brought greater obstacles to blocking the activation of RIG-I, thereby being able to more strictly and effectively inhibit the occurrence of immune response. On this basis, the present invention was completed.
[0067] The present invention provides a capped analogue having a structure as shown in formula (I):
[0068]
[0069] Wherein, B1 and B2 are natural or modified bases, respectively;
[0070] E and F are 0 or 1 respectively;
[0071] R1 is H, OH, alkyl, O-alkyl (such as but not limited to, O-methyl), halogen, or oxygen and the oxygen forms a bridged ring with the C at the 3' and 5' positions;
[0072] R2 is H, OH, alkyl, O-alkyl (such as but not limited to, O-methyl) or halogen;
[0073] R3 is O-R5-R6;
[0074] R4 is hydrogen, hydroxy, O-methyl or O-R5-R6;
[0075] R5 is substituted or unsubstituted C 1-20 alkyl;
[0076] R6 is substituted or unsubstituted O-alkyl, substituted or unsubstituted S-alkyl, substituted or unsubstituted NH-alkyl, substituted or unsubstituted N-dialkyl, substituted or unsubstituted O-aryl, substituted or unsubstituted S-aryl, substituted or unsubstituted NH-aryl, substituted or unsubstituted O-aralkyl, substituted or unsubstituted S-aralkyl, or substituted or unsubstituted NH-aralkyl;
[0077] When R5 is substituted or unsubstituted C 2-20 When it is alkyl, R6 can be hydrogen;
[0078] X1, X2 and X3 are O, CH2 or NH respectively;
[0079] Y1, Y2 and Y3 are O, S, Se, or BH3 respectively.
[0080] In one embodiment of the present invention, R6 is hydrogen and R5 is substituted or unsubstituted C2-5 Alkyl, R3 and R4 are respectively but not limited to O-ethyl, O-propyl, O-isopropyl, O-butyl, O-isobutyl, O-tert-butyl, O-pentyl, etc.; or R4 is hydroxyl, R3 is but not limited to O-ethyl, O-propyl, O-isopropyl, O-butyl, O-isobutyl, O-tert-butyl, O-pentyl, etc.
[0081] In one embodiment of the present invention, R5 is substituted or unsubstituted C 1-5 Alkyl and R6 is substituted or unsubstituted C 1-5The R3 and R4 are respectively, but not limited to, O-methylene-O-methyl, O-ethylene-O-methyl, O-propylene-O-methyl, O-butylene-O-methyl, O-pentylene-O-methyl, O-methylene-O-ethyl, O-methylene-O-propyl, O-methylene-O-isopropyl, O-methylene-O-butyl, O-methylene-O-isobutyl, O-methylene-O-tert-butyl, O-methylene-O-pentyl, O-ethylene-O-ethyl, O-ethylene-O-propyl, O-ethylene-O-isopropyl, O-ethylene-O-butyl, O-ethylene-O-isobutyl, O-ethylene-O-tert-butyl, O-ethylene-O-pentyl, O-ethylene-O-ethyl, O-ethylene-O-propyl, O-ethylene-O-isopropyl, O-ethylene-O-butyl, O-ethylene-O-isobutyl, O-ethylene-O-tert-butyl, O-ethylene-O-pentyl, O-ethylene Propyl-O-ethyl, O-propylene-O-propyl, O-propylene-O-isopropyl, O-propylene-O-butyl, O-propylene-O-isobutyl, O-propylene-O-tert-butyl, O-propylene-O-pentyl, O-butylene-O-ethyl, O-butylene-O-propyl, O-butylene-O-isopropyl, O-butylene-O-butyl, O-butylene-O-isobutyl, O-butylene-O-tert-butyl, O-butylene-O-pentyl, O-pentyl-O-ethyl, O-pentyl-O-propyl, O-pentyl-O-isopropyl, O-pentyl-O-butyl, O-pentyl-O-isobutyl, O-pentyl-O-tert-butyl, O-pentyl-O-pentyl, etc. ; Or R4 is hydroxyl, R3 is but not limited to, O-methylene-O-methyl, O-ethylidene-O-methyl, O-propylene-O-methyl, O-butylidene-O-methyl, O-pentyl-O-methyl, O-methylene-O-ethyl, O-methylene-O-propyl, O-methylene-O-isopropyl, O-methylene-O-butyl, O-methylene-O-isobutyl, O-methylene-O-tert-butyl, O-methylene-O-pentyl, O-ethylidene-O-ethyl, O-ethylidene-O-propyl, O-ethylidene-O-isopropyl, O-ethylidene-O-butyl, O-ethylidene-O-isobutyl, O-ethylidene-O-tert-butyl, O-ethylidene-O-pentyl, O-propylene O-butylene-O-isobutyl, O-butylene-O-tert-butyl, O-butylene-O-pentyl, O-butylene-O-ethyl, O-butylene-O-propyl, O-butylene-O-isopropyl, O-butylene-O-butyl, O-butylene-O-tert-butyl, O-butylene-O-pentyl, O-pentylene-O-ethyl, O-pentylene-O-propyl, O-pentylene-O-isopropyl, O-pentylene-O-butyl, O-pentylene-O-isobutyl, O-pentylene-O-tert-butyl, O-pentylene-O-pentyl, and the like.
[0082] Representative tri-oligonucleic acid polymers of the capped analogs of formula (I) of the present invention are shown in the following table:
[0083]
[0084]
[0085]
[0086]
[0087] In one embodiment of the present invention, the capped analog provided has a structure as shown in the following formula (Ia) or formula (Ib), wherein formula (Ia) and formula (Ib) are different stereo conformations, wherein formula (Ia) is a β conformation and formula (Ib) is an α conformation:
[0088]
[0089] Wherein, B1 and B2 are natural or modified bases, respectively;
[0090] R3 is O-R5-R6.
[0091] R5 is substituted or unsubstituted C 1-20 alkyl;
[0092] R6 is substituted or unsubstituted O-alkyl, substituted or unsubstituted S-alkyl, substituted or unsubstituted NH-alkyl, substituted or unsubstituted N-dialkyl, substituted or unsubstituted O-aryl, substituted or unsubstituted S-aryl, substituted or unsubstituted NH-aryl, substituted or unsubstituted O-aralkyl, substituted or unsubstituted S-aralkyl, or substituted or unsubstituted NH-aralkyl;
[0093] When R5 is substituted or unsubstituted C 2-20 In the case of an alkyl group, R6 may be hydrogen.
[0094] In one embodiment of the present invention, in formula (Ia) or formula (Ib), R6 is hydrogen and R5 is substituted or unsubstituted C 2-5 Alkyl, said R3 is but not limited to, O-ethyl, O-propyl, O-isopropyl, O-butyl, O-isobutyl, O-tert-butyl, O-pentyl and the like.
[0095] In one embodiment of the present invention, R5 in Formula (Ia) or Formula (Ib) is substituted or unsubstituted C 1-5 Alkyl and R6 is substituted or unsubstituted C 1-5Alkyl, wherein R3 is, but is not limited to, O-methylene-O-methyl, O-ethylene-O-methyl, O-propylene-O-methyl, O-butylene-O-methyl, O-pentylene-O-methyl, O-methylene-O-ethyl, O-methylene-O-propyl, O-methylene-O-isopropyl, O-methylene-O-butyl, O-methylene-O-isobutyl, O-methylene-O-tert-butyl, O-methylene-O-pentyl, O-ethylene-O-ethyl, O-ethylene-O-propyl, O-ethylene-O-isopropyl, O-ethylene-O-butyl, O-ethylene-O-isobutyl, O-ethylene-O-tert-butyl, O-ethylene-O-pentyl, O-propylene-O O-butylene-O-propyl, O-propylene-O-isopropyl, O-propylene-O-butyl, O-propylene-O-isobutyl, O-propylene-O-tert-butyl, O-propylene-O-pentyl, O-butylene-O-ethyl, O-butylene-O-propyl, O-butylene-O-isopropyl, O-butylene-O-butyl, O-butylene-O-isobutyl, O-butylene-O-tert-butyl, O-butylene-O-pentyl, O-pentyl-O-ethyl, O-pentyl-O-propyl, O-pentyl-O-isopropyl, O-pentyl-O-butyl, O-pentyl-O-isobutyl, O-pentyl-O-tert-butyl, O-pentyl-O-pentyl, etc.; or wherein R4 is hydroxyl, and R3 is, but is not limited to, O-methylene-O-methyl, O-ethylene-O-methyl, O-propylene-O-methyl, O-butylene-O-methyl, O-pentylene-O-methyl, O-methylene-O-ethyl, O-methylene-O-propyl, O-methylene-O-isopropyl, O-methylene-O-butyl, O-methylene-O-isobutyl, O-methylene-O-tert-butyl, O-methylene-O-pentyl, O-ethylene-O-ethyl, O-ethylene-O-propyl, O-ethylene-O-isopropyl, O-ethylene-O-butyl, O-ethylene-O-isobutyl, O-ethylene-O-tert-butyl, O-ethylene-O-pentyl, O-ethylene-O-ethyl, O-ethylene-O-propyl, O-ethylene-O-isopropyl, O-ethylene-O-butyl, O-ethylene-O-isobutyl, O-ethylene-O-tert-butyl, O-ethylene-O-pentyl, O-propylene -O-ethyl, O-propylene-O-propyl, O-propylene-O-isopropyl, O-propylene-O-butyl, O-propylene-O-isobutyl, O-propylene-O-tert-butyl, O-propylene-O-pentyl, O-butylene-O-ethyl, O-butylene-O-propyl, O-butylene-O-isopropyl, O-butylene-O-butyl, O-butylene-O-isobutyl, O-butylene-O-tert-butyl, O-butylene-O-pentyl, O-pentyl-O-ethyl, O-pentyl-O-propyl, O-pentyl-O-isopropyl, O-pentyl-O-butyl, O-pentyl-O-isobutyl, O-pentyl-O-tert-butyl, O-pentyl-O-pentyl, and the like.
[0096] The present invention also provides a method for preparing a capped analogue having a structure as shown in Formula (I), Formula (Ia) or Formula (Ib), for example but not limited to, by an oligonucleotide solid phase synthesis process, the steps comprising:
[0097] (1) Using the raw material 5'-O-DMT-2'-O-TBDMS phosphoramidite (rA Ac ,rC Ac ,rG dmf ,U), 2'-O-MOE-3'-O-phosphoramidite(A 2’O-MOE Ac ,C 2’O-MOE Ac ,G 2’O-MOE dmf U 2’O-MOE,) and 2'-O-Ethyl-3'-O-phosphoramidite(A 2’O-Ethyl Ac ,C 2’O-Ethyl Ac ,G 2’O-Ethyl dmf , U 2’O-Ethyl,) , Bis-cyanoethyl-N,N-diisopropyl CED phosphoramidite, etc., by using a solid phase synthesis instrument to synthesize pNpN dinucleotides;
[0098] (2) 7me-2'-O-4'-C-Locked-Guanosine 5'-diphosphate ( m7 G Beta-D-LNA DPIm) or 2'-O,4'-C-methylene-alfa-L-ribofuranosylGuanosine 5'-diphosphate( m7 G Alpha-L-LNA DPIm) or N7-methylguanosine 5'-diphosphate( m7 GDPIm) reaction to generate a capped analogue with a structure as shown in Formula (I), Formula (Ia) or Formula (Ib).
[0099] In one embodiment of the present invention, the method further comprises the step of purifying the obtained capped analogs, for example but not limited to, purification by DEAE-650s (Toyopearl) and semi-preparative RT-HPLC columns.
[0100] The present invention also uses the capped analogues shown in formula (I), formula (Ia) or formula (Ib) to synthesize mRNA by in vitro transcription, comprising the steps of:
[0101] The first step is to prepare template DNA;
[0102] The second step is to prepare the mixed enzyme and the reaction buffer;
[0103] The third step is to perform in vitro transcription reaction;
[0104] Step 4: dephosphorylation;
[0105] Step 5: purify the reaction solution.
[0106] In the first step, the template usually consists of a linear plasmid, which has a target sequence inserted into the multiple cloning site and a promoter of a corresponding polymerase, such as T7, T3 or SP6 promoter, in front of the target sequence. The plasmid needs to be linearized before use, and the DNA can be linearized by digestion with a suitable restriction endonuclease commonly known in the art, and then purified, for example, but not limited to, by treatment with phenol chloroform and then ethanol precipitation.
[0107] Generally, restriction enzymes used to linearize plasmids should have blunt ends or 5' overhangs (linearizing the template with enzymes that produce 3' overhangs will result in aberrant transcripts).
[0108] In the second step, RNA polymerase, nuclease inhibitor, pyrophosphatase, etc. can be used to prepare the mixed enzyme.
[0109] The reaction buffer prepared in the second step includes, but is not limited to, Tris-HCl (pH 7.9), MgCl2, spermidine, dithiothreitol (DTT), and Triton X-100.
[0110] In the third step, the capping analog provided by the present invention can be used to perform an in vitro transcription reaction.
[0111] The reagents that can be used for the dephosphorylation treatment in the fourth step may include, but are not limited to, Antarctic TAB5 phosphatase, shrimp alkaline phosphatase, calf alkaline phosphatase, and the like.
[0112] The fifth step can be purified using conventional methods in the art, such as, but not limited to, high performance liquid chromatography, lithium chloride precipitation, ammonium acetate precipitation, and the like.
[0113] The present invention also provides a polynucleotide encoding a target polypeptide comprising the provided capping analog, and a pharmaceutical composition containing the polynucleotide encoding the target polypeptide.
[0114] Unless otherwise specified, the following terms used in the specification and claims have the following meanings:
[0115] As used in the present invention, "capping analogue" refers to a structure at the 5' end of mature mRNA formed by post-transcriptional modification in eukaryotic organisms, i.e., m 7 The GPPPN structure, also known as the methylguanosine cap, can prevent mRNA from being degraded at the 5' end, help RNA transcription products pass through the selective pores of the nuclear membrane and enter the cytoplasm, enhance translation, and help complete the entire shearing process.
[0116] As used in the present invention, "base" and "natural base" can be used interchangeably, and both can be called nucleobases, nitrogenous bases, which are nitrogen-containing compounds that form nucleosides, which are components of nucleotides; they can be adenine (A), guanine (G), cytosine (C), uracil (U), or thymine (T).
[0117] A "modified base" refers to a base in which one or more hydrogen atoms of a natural base are replaced, such as, but not limited to, N6-methyladenine.
[0118] "Alkyl" refers to an aliphatic hydrocarbon group. The alkyl portion may be a saturated alkyl (meaning that it does not contain any unsaturated units, such as a carbon-carbon double bond or a carbon-carbon triple bond) or the alkyl portion may be an unsaturated alkyl (meaning that it contains at least one unsaturated unit). The alkyl portion, whether saturated or unsaturated, may be branched or straight chain. There may be 1 to 8 carbon atoms (as long as it appears here, a numerical range such as "1 to 8" refers to each integer in the given range, such as "1 to 8 carbon atoms" refers to an alkyl group that may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. until it contains 8 carbon atoms, although the current definition also includes the appearance of the term "alkyl" without specifying a numerical range). The alkyl group of the compounds described herein may be designated as "C1-C6 alkyl" or a similar designation. For example, "C1-C6 alkyl" refers to having one, two, three, four, five or six carbon atoms in the alkyl chain. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.
[0119] "Aralkyl" means an -alkyl-aryl group in which alkyl and aryl are as defined herein.
[0120] "Halogen" refers to fluorine, chlorine, bromine and iodine.
[0121] An "alkoxy" group refers to an "O-alkyl" group, with alkyl being as defined herein.
[0122] "Aromatic" refers to a planar ring having a delocalized π electron system containing 4n+2π electrons, where n is an integer. Aromatic rings may consist of five, six, seven, eight, nine, ten or more atoms. Aromatic rings are optionally substituted. The term "aromatic" includes carbocyclic aromatic groups ("aryl" such as phenyl) and heterocyclic aromatic groups (or "heteroaryl" or "aromatic heterocycle") (such as pyridine).
[0123] "Substituted" means that the referenced group may be substituted with one or more additional groups individually and independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, cyano, halo, carbonyl, thiocarbonyl, nitro, haloalkyl, fluoroalkyl and amino, including mono- and di-substituted amino groups and protected derivatives thereof. By way of example, the substituents are selected from the group consisting of halogen, CF3, OH, CN, NO2, SO3H, SO2NH2, SO2Me, NH2, COOH, CONH2, alkoxy, -N(CH3)2 and alkyl.
[0124] The term "pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmacologically acceptable excipients or carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0125] The main advantage of the present invention is that the capped analogs provided by the present invention can effectively inhibit the occurrence of immune response.
[0126] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here.
[0127] In the following description, each specific aspect, characteristic and advantage of the above-mentioned compounds, methods and pharmaceutical compositions will be described in detail to make the content of the present invention become very clear. It should be understood that the following detailed description and examples describe specific embodiments and are only for reference. After reading the description of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these changes or modifications also belong to the scope limited by the application.
[0128] The present invention is explained in more detail in the following examples. However, it should be understood that these examples are for illustrating the present invention and are not intended to limit the scope of the present invention in any way. The experimental methods in the following examples that do not specify specific conditions are usually carried out under normal conditions or according to the conditions recommended by the manufacturer. Unless otherwise stated, parts and percentages are by weight. The organic solvents used in the reactions of the embodiments are all treated with drying methods known in the art.
[0129] The LC-MS analysis method involved in the capping efficiency determination in the following examples is as follows:
[0130] Equipment: Waters UPLC H-Class
[0131] Column: ACQUITY UPLC Oligonucleotide BEH C18, 2.1*150mm
[0132] Column temperature: 75°C
[0133] Mobile phase A: 200 mM hexafluoroisopropanol + 8.15 mM triethylamine pH 7.9
[0134] Mobile phase B: methanol
[0135] Flow rate: 0.3mL / min
[0136] gradient:
[0137] Time (min) B% 0 5 1 5 13 25 17 40 25 5
[0138] MS equipment: Waters SQ Detector 2
[0139] Ion source: ESI
[0140] Ionization mode: ES -
[0141] M / Z:600~3000
[0142] Example 1
[0143] A brief description of the synthetic route of capped analogs
[0144] Synthesis of capped analogs: starting material 5'-O-DMT-2'-O-TBDMS phosphoramidite (rA Ac C Ac ,rG dmf ,U) and 2'-O-MOE-3'-O-phosphoramidite (A 2’O-MOE Ac ,C 2’O-MOE Ac ,G 2’O-MOE dmf U 2’O-MOE,) and 2'-O-Ethyl-3'-O-phosphoramidite(A 2’O-Ethyl Ac ,C 2’O-Ethyl Ac ,G 2’O-Ethyl dmf , U 2’O-Ethyl,) The pNpN dinucleotide was synthesized using the common oligonucleotide solid phase synthesis process (Bioautomation Mermade 12 solid phase synthesis instrument) and then reacted with 7me-2'-O-4'-C-Locked-Guanosine 5'-diphosphate ( m7 G Beta-D-LNA DPIm) or 2'-O,4'-C-methylene-alfa-L-ribofuranosylGuanosine 5'-diphosphate( m7 G Alpha-L-LNA DPIm) or N7-methylguanosine 5'-diphosphate( m7 GDPIm) reaction to generate the initial capping oligonucleotide composition, which was purified by DEAE-650s (Toyopearl) and semi-preparative RT-HPLC column to obtain the pure product. The synthesis process is shown in Figure 1-3 .
[0145] Example 2
[0146] Synthesis of mRNA containing capped analogs
[0147] (1) Preparation of template DNA
[0148] Typically, the template consists of a linearized plasmid with the target sequence inserted in the multiple cloning site and a promoter for the corresponding polymerase in front of the target sequence, such as T7, T3 or SP6 promoter. The plasmid needs to be linearized before use, and the DNA is linearized by digestion with a suitable restriction endonuclease, and then purified by appropriate methods, such as phenol chloroform treatment, followed by ethanol precipitation. The restriction endonuclease used to linearize the plasmid should be blunt-ended or have a 5' overhang (using an enzyme that produces a 3' overhang to linearize the template will result in abnormal transcripts).
[0149] (2) Preparation of mixed enzyme
[0150] Enzyme Mix Final concentration T7 RNA polymerase 100U / ul Inorganic pyrophosphatase 0.1U / ul Nuclease inhibitors 20U / ul
[0151] (3) Prepare 10× reaction buffer
[0152] 10× reaction buffer Final concentration HEPES-NaOH pH7.5@25℃ 400mM Magnesium chloride 200mM Spermidine 10mM Dithiothreitol 100mM
[0153] (4) T7 in vitro transcription reaction
[0154]
[0155]
[0156] The capped analogs are m7 GpppApG, m7 G pppA 2’Ome pG, m7 G 3’Ome pppA 2’O-ethyl pG, m7 G 2’ Ome pppA 2’O-ethyl pG, m7 G 3’Ome pppA 2’O-MOE pG, m7 G 2’Ome pppA 2’O-MOE pG, m7 Gppp(N6-methyladenine) 2’O-MOE pG), m7 G 2’Ome pppC 2’O-ethyl pC, m7 G 3’Ome pppA 2’O-MOE pU.
[0157] 37℃ for 2h,
[0158] Add 1U of DNase I and react at 37℃ for 30mins.
[0159] (5) Antarctic phosphatase treatment:
[0160] Utilize Thermo MEGAclear TM The reaction solution was purified using Transcription Clean-Up Kit, and 2ul of 5U / ul Antarctic phosphatase was added to the purified mRNA. The mixture was mixed and incubated at 37°C for 1h.
[0161] After treatment, the mRNA yield was analyzed using a spectrophotometer. The yield results are shown in Table 1.
[0162] (6) Purification of reaction solution
[0163] Purify by HPLC, Buffer B (0.1 M triethylamine-acetic acid pH 7.0 and 25% acetonitrile), Buffer A (0.1 M triethylamine-acetic acid pH 7.0), gradient from 30% to 60% Buffer A, approximately 30 min, 1 ml / min, combine the fractions containing RNA, precipitate with isopropanol, and quantify by spectrophotometer.
[0164] (7) Determination of capping efficiency
[0165] For each starting capping oligonucleotide tested, the proportion of capped mRNA will be analyzed by liquid chromatography mass spectrometry (LC-MS) detection results. In this experiment, a DNA probe is complementary to the mRNA. When RNA and DNA hybridize, RNaseH will specifically hydrolyze the phosphodiester bond in the RNA. Under the action of RNaseH, a small fragment of RNA with a uniform 3' end is obtained. The molecular weight and percentage of the small fragment RNA are analyzed by LC-MS to determine the capping of the RNA in the transcription reaction. Since the presence or absence of a cap at the 5' end can be seen in the molecular weight, the capping efficiency can be obtained by analyzing the molecular weight and percentage of the short RNA containing the 5' end. At the same time, it can be calculated from the molecular weight that the added cap is the capping nucleotide obtained through the synthesis path of Example 1 above. The results of the capping efficiency are shown in Tables 1 and Fig.12 .
[0166] (8) Protein expression identification
[0167] In this example, luciferase mRNA (Gaussia luciferase) with different initial capping structures (including the initial capping nucleotide structure: m7 GpppApG, m7 GpppA 2’Ome pG, m7 G 3’Ome pppA 2’O-ethyl pG, m7 G2’ Ome pppA 2’O-ethyl pG, m7 G 3’Ome pppA 2’O-MOE pG, m7 G 2’Ome pppA 2’O-MOE pG, m7 Gppp(N6-methyladenine) 2’O-MOE pG, m7 G 2’Ome pppC 2’O-ethyl pC, m7 G 3’Ome pppA 2’O-MOE pU) were transfected into Hela cells (ATCCCCL-2), and the signal intensity of luciferase was detected by microplate reader 24 hours later. The fluorescence signal intensity was proportional to the protein expression abundance. 5 The cells were plated at a density of 1 / well in a 6-well plate, and transfection was performed when the cell density was approximately 80%. 2ug mRNA was transfected into each well, and the transfection reagent was Lipofectamine MessengerMAX Transfection Reagent (Invitrogen). The transfection steps were performed according to the instructions. 24 hours after transfection, the signal intensity of luciferase was measured using a microplate reader. Determination of luciferase fluorescence: first transfer the transfected cell culture medium to a 1.5mL centrifuge tube and centrifuge, take 10ul of the cell supernatant and add it to a 96-well plate, and add 50ul of 10ng / ml of substrate, and measure its fluorescence intensity on a Synergy HI (BioTek) instrument. The expression of each mRNA needs to be measured 6 times, and the expression results are relative to m7 The relative value of the GpppApG cap result. The data are expressed as mean ± standard deviation, and the results are shown in Table 1. At the same time, the protein expression identification of the unpurified mRNA was completed, and the results are shown in Tables 1 and Figure 4 .
[0168] Table 1: Statistics of mRNA with different initial capping nucleotides
[0169]
[0170] (9) Determination of mRNA binding ability to RIG-I and IFIT1
[0171] In this example, luciferase mRNA (Gaussia luciferase) with different initial capping structures (including the initial capping nucleotide structure: m7 GpppApG, m7GpppA 2’Ome pG, m7 G 3’Ome pppA 2’O-ethyl pG, m7 G 2’ Ome pppA 2’O-ethyl pG, m7 G 3’Ome pppA 2’O-MOE pG, m7 G 2’Ome pppA 2’O-MOE pG, m7 Gppp(N6-methyladenine) 2’O-MOE pG, m7 G 2’Ome pppC 2’O-ethyl pC, m7 G 3’Ome pppA 2’O-MOE pU) were transfected into Hela cells (ATCCCCL-2). After 24 hours, the cells were collected and the intracellular proteins RIG-I and IFIT1 were immunoprecipitated together with their bound RNA using RNA immunoprecipitation. Finally, these mRNAs were reverse transcribed and subjected to real-time quantitative PCR. The relative abundance of these mRNAs was positively correlated with their binding ability to RIG-I and IFIT1.
[0172] Hela cells were collected at 4×10 5 The cells were plated in a 6-well plate at a density of 100 μg / well. The cells were transfected when the cell density was about 80%. Each well was transfected with 2 μg mRNA. The transfection reagent was Lipofectamine MessengerMAX Transfection Reagent (Invitrogen). The transfection steps were carried out according to the instructions. After 24 hours, the cells were collected, and the fixative was added to the cells and incubated at room temperature for 10 minutes. Then, the appropriate concentration of glycine was added to terminate the reaction, and the cells were collected by centrifugation. An appropriate amount of lysis buffer was added to the cells, incubated on ice for 30 minutes, centrifuged and the supernatant was collected. An appropriate amount (2-4 ng) of RIG-I and IFIT1 antibodies (Abcam) were added to the supernatant and incubated overnight at 4°C on a shaker. Then, 20 μl of Protein A / G magnetic beads were added to it and incubated at 4°C on a shaker for 2 hours. The beads were washed 3 times with a magnetic stand for 5 minutes each time. After that, 1 mL of TRIzol reagent was added to the magnetic beads to extract RNA, and the RNA was reversely transcribed into cDNA. Finally, the expression of related genes was detected by real-time quantitative fluorescence PCR, and the internal reference gene was β-ACTIN. The detection of each gene needs to be repeated three times, and the expression results of each gene are relative to m7The relative value of the GpppApG hat result. The data are expressed as mean ± standard deviation. The results are shown in Table 2. Figure 5 and 6 .
[0173] Table 2 Statistics of the ability of mRNA with different initial capping nucleotides to bind to RIG-I and IFIT1
[0174]
[0175] (10) Immunogenicity assay
[0176] In this example, luciferase mRNA (Gaussia luciferase) with different initial capping structures (including the initial capping nucleotide structure: m7 GpppApG, m7 GpppA 2’Ome pG, m7 G 3’Ome pppA 2’O-ethyl pG, m7 G 2’ Ome pppA 2’O-ethyl pG, m7 G 3’Ome pppA 2’O-MOE pG, m7 G 2’Ome pppA 2’O-MOE pG, m7 Gppp(N6-methyladenine) 2’O-MOE pG, m7 G 2’Ome pppC 2’O-ethyl pC, m7 G 3’Ome pppA 2’O-MOE pU) were transfected into Hela cells (ATCCCCL-2), and the cells were collected 24 hours later to detect the expression of intracellular inflammatory factors. The relative abundance of inflammatory factors was positively correlated with the immunogenicity of mRNA.
[0177] Hela cells were collected at 4×10 5The cells were plated at a density of 100 μg / well in a 6-well plate, and transfection was performed when the cell density was approximately 80%. Each well was transfected with 2 ug of mRNA, and the transfection reagent was Lipofectamine MessengerMAX Transfection Reagent (Invitrogen). The transfection steps were performed according to the instructions. After 24 hours, the cells were collected, RNA was extracted using TRIzol, and the RNA was reverse transcribed into cDNA. Finally, real-time quantitative fluorescence PCR was used to detect the expression of intracellular inflammatory factors, and the internal reference gene was β-ACTIN. The detection of each gene needs to be repeated three times, and the expression results of each gene are relative to m7 The relative value of the GpppApG hat result. The data are expressed as mean ± standard deviation, and the results are shown in Table 3 and Figure 7 .
[0178] Table 3 Statistics of immunogenicity of mRNA with different initial capping nucleotides
[0179]
[0180]
[0181] Example 3
[0182] Capped analogs m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L-LNA pppA 2’O-ethyl Preparation and expression of pG mRNA
[0183] (1) Preparation of template DNA
[0184] Typically, the template consists of a linearized plasmid with the target sequence inserted in the multiple cloning site and a promoter for the corresponding polymerase in front of the target sequence, such as T7, T3 or SP6 promoter. The plasmid needs to be linearized before use, and the DNA is linearized by digestion with a suitable restriction endonuclease, and then purified by appropriate methods, such as phenol chloroform treatment, followed by ethanol precipitation. The restriction endonuclease used to linearize the plasmid should be blunt-ended or have a 5' overhang (using an enzyme that produces a 3' overhang to linearize the template will result in abnormal transcripts).
[0185] (2) Preparation of mixed enzyme
[0186] Enzyme Mix Final concentration Thermostable T7 RNA Polymerase (NEB) 100U / ul Thermostable Inorganic Pyrophosphatase (NEB) 0.1U / ul Nuclease inhibitors 20U / ul
[0187] (3) Prepare 10× reaction buffer
[0188] 10× reaction buffer Final concentration HEPES-NaOH pH7.5@25℃ 400mM Magnesium chloride 200mM Spermidine 10mM Dithiothreitol 100mM
[0189] (4) T7 in vitro transcription reaction
[0190]
[0191]
[0192] The starting capping oligonucleotides are m7 GpppApG, m7 G pppA 2’Ome pG (control), m7 G Beta-D- LNA pppA 2’O-MOE pG and m7 G Alpha-L-LNA pppA 2’O-ethyl pG.
[0193] 50℃ for 2h,
[0194] Add 1U of DNase I and react at 37℃ for 30mins.
[0195] (5) Antarctic phosphatase treatment:
[0196] Utilize Thermo MEGAclear TM The reaction solution was purified using Transcription Clean-Up Kit, and 2ul of 5U / ul Antarctic phosphatase was added to the purified mRNA. The mixture was mixed and incubated at 37°C for 1h.
[0197] After treatment, the mRNA yield was analyzed using a spectrophotometer. The yield results are shown in Table 4.
[0198] (6) Purification of reaction solution
[0199] Purify by HPLC, Buffer B (0.1 M triethylamine-acetic acid pH 7.0 and 25% acetonitrile), Buffer A (0.1 M triethylamine-acetic acid pH 7.0), gradient from 30% to 60% Buffer A, approximately 30 min, 1 ml / min, combine the fractions containing RNA, precipitate with isopropanol, and quantify by spectrophotometer.
[0200] (7) Determination of capping efficiency
[0201] For each starting capping oligonucleotide tested, the proportion of capped mRNA will be analyzed by liquid chromatography mass spectrometry (LC-MS) detection results. In this experiment, a DNA probe is complementary to the mRNA. When RNA and DNA hybridize, RNaseH will specifically hydrolyze the phosphodiester bond in the RNA. Under the action of RNaseH, a small fragment of RNA with a uniform 3' end is obtained. The molecular weight and percentage of the small fragment RNA are analyzed by LC-MS to determine the capping of the RNA in the transcription reaction. Since the presence or absence of a cap at the 5' end can be seen in the molecular weight, the capping efficiency can be obtained by analyzing the molecular weight and percentage of the short RNA containing the 5' end. At the same time, it can be calculated from the molecular weight that the added cap is the capping nucleotide. The results of the capping efficiency are shown in Tables 4 and Fig.13 .
[0202] (8) Protein expression identification
[0203] In this example, luciferase mRNA (Gaussia luciferase) with different initial capping structures (including the initial capping nucleotide structure: m7 GpppApG, m7 G pppA 2’Ome pG, m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L- LNA pppA 2’O-ethyl pG) was transfected into Hela cells (ATCC CCL-2), and the signal intensity of luciferase was detected by microplate reader after 24 hours. The fluorescence signal intensity was proportional to the protein expression abundance.
[0204] Hela cells were collected at 4×10 5 The cells were plated at a density of 1 / well in a 6-well plate, and transfection was performed when the cell density was approximately 80%. 2ug mRNA was transfected into each well, and the transfection reagent was Lipofectamine MessengerMAX Transfection Reagent (Invitrogen). The transfection steps were performed according to the instructions. 24 hours after transfection, the signal intensity of luciferase was measured using a microplate reader. Determination of luciferase fluorescence: first transfer the transfected cell culture medium to a 1.5mL centrifuge tube and centrifuge, take 10ul of the cell supernatant and add it to a 96-well plate, and add 50ul of 10ng / ml of substrate, and measure its fluorescence intensity on a Synergy HI (BioTek) instrument. The expression of each mRNA needs to be measured 6 times, and the expression results are relative to m7The relative value of the GpppApG cap result. The data are expressed as mean ± standard deviation, and the results are shown in Table 4. At the same time, the protein expression identification of the unpurified mRNA was completed, and the results are shown in Table 4 and Figure 8 .
[0205] Table 4 Initial capping nucleotides m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L-LNA pppA 2’O-ethyl pG mRNA statistics
[0206]
[0207] (9) Determination of mRNA binding ability to RIG-I and IFIT1
[0208] In this example, luciferase mRNA (Gaussia luciferase) with different initial capping structures (including the initial capping nucleotide structure: m7 GpppApG, m7 G pppA 2’Ome pG, m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L- LNA pppA 2’O-ethyl pG) were transfected into Hela cells (ATCC CCL-2). After 24 hours, the cells were collected and the intracellular proteins RIG-I and IFIT1 were immunoprecipitated together with their bound RNA using RNA immunoprecipitation. Finally, these mRNAs were reverse transcribed and subjected to real-time quantitative PCR. Their relative abundance was proportional to their binding ability with RIG-I and IFIT1.
[0209] Hela cells were collected at 4×10 5The cells were plated in a 6-well plate at a density of 100 μg / well. The cells were transfected when the cell density was about 80%. Each well was transfected with 2 μg mRNA. The transfection reagent was Lipofectamine MessengerMAX Transfection Reagent (Invitrogen). The transfection steps were carried out according to the instructions. After 24 hours, the cells were collected, and the fixative was added to the cells and incubated at room temperature for 10 minutes. Then, the appropriate concentration of glycine was added to terminate the reaction, and the cells were collected by centrifugation. An appropriate amount of lysis buffer was added to the cells, incubated on ice for 30 minutes, centrifuged and the supernatant was collected. An appropriate amount (2-4 ng) of RIG-I and IFIT1 antibodies (Abcam) were added to the supernatant and incubated overnight on a shaker at 4 degrees. Then, 20 μl of Protein A / G magnetic beads were added to it and incubated on a shaker at 4 degrees for 2 hours. The beads were washed 3 times with a magnetic stand for 5 minutes each time. After that, 1 mL of TRIzol reagent was added to the magnetic beads to extract RNA, and the RNA was reversely transcribed into cDNA. Finally, the expression of related genes was detected by real-time quantitative fluorescence PCR, and the internal reference gene was β-ACTIN. The detection of each gene needs to be repeated three times, and the expression results of each gene are relative to m7 The relative value of the GpppApG hat result. The data are expressed as mean ± standard deviation. The results are shown in Table 5. Fig. 9 and 10 .
[0210] Table 5 Initial capping nucleotides m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L-LNA pppA 2’O-ethyl Data statistics of pG mRNA binding ability to RIG-I and IFIT1
[0211]
[0212] (10) Immunogenicity assay
[0213] In this example, luciferase mRNA (Gaussia luciferase) with different initial capping structures (including the initial capping nucleotide structure: m7 GpppApG, m7 G pppA 2’Ome pG, m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L- LNA pppA 2’O-ethylpG) were transfected into Hela cells (ATCC CCL-2), and the cells were collected 24 hours later to detect the expression of intracellular inflammatory factors, whose relative abundance was positively correlated with the immunogenicity of mRNA. Hela cells were transfected with 4×10 5 The density of cells per well was plated in a 6-well plate, and transfection was performed when the cell density was about 80%. 2ug mRNA was transfected into each well, and the transfection reagent was Lipofectamine Messenger MAX Transfection Reagent (Invitrogen). The transfection steps were performed according to the instructions. After 24 hours, the cells were collected, RNA was extracted using TriZol, and RNA was reverse transcribed into cDNA. Finally, real-time quantitative fluorescence PCR was used to detect the expression of intracellular inflammatory factors, and the internal reference gene was β-ACTIN. The detection of each gene needs to be repeated three times, and the expression result of each gene is relative to m7 The relative value of the GpppApG hat result. The data are expressed as mean ± standard deviation, and the results are shown in Table 6 and Fig.11 .
[0214] Table 6 Initial capping nucleotides m7 G Beta-D-LNA pppA 2’O-MOE pG and m7 G Alpha-L-LNA pppA 2’O-ethyl Statistics of pG mRNA immunogenicity
[0215]
[0216] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of the substantial technical content of the present invention. The substantial technical content of the present invention is broadly defined in the scope of the claims of the application. Any technical entity or method completed by others, if it is exactly the same as that defined in the scope of the claims of the application or an equivalent variation, will be deemed to be included in the scope of the claims.
Claims
1. A capped analogue of formula (I): Wherein, B1 is adenine or N6-methyladenine, and B2 is guanine; E and F are 0 or 1 respectively and not simultaneously; R1 is H, OH or O-methyl; R2 is H, OH or O-methyl; R3 is independently selected from: O-ethyl or O-ethylene-O-methyl; R4 is a hydroxyl group; X1, X2 and X3 are O; Y1, Y2 and Y3 are O.
2. The capped analog according to claim 1, characterized in that R1 is -OH.
3. The capped analog according to claim 1, characterized in that R2 is O-methyl.
4. The capped analog according to claim 1, characterized in that The capped analog is selected from: m7 G 3’ Ome pppA 2’O-ethyl pG, m7 G 2’Ome pppA 2’O-ethyl pG.
5. The capped analog according to claim 1, characterized in that The structure of the capped analog is shown in Formula (Ia) or Formula (Ib): In the formula, B1 is adenine, B2 is guanine; R3 is O-ethyl or O-ethylene-O-methyl.
6. The capped analog according to claim 5, characterized in that The capped analog is 7 G Alpha-L- LNA pppA 2’O-ethyl pG.
7. A polynucleotide encoding a target polypeptide, characterized in that: The polynucleotide comprises: (a) at least one ORF region; (b) a 5'UTR with at least one Kozak sequence; (c) 3'UTR; and (d) at least one 5'-initial capped capping analogue according to any one of claims 1 to 6.
8. A pharmaceutical composition, characterized in that It contains the polynucleotide as claimed in claim 7 and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition according to claim 8, characterized in that The carrier is selected from lipid nanoparticles, liposomes, polymer nanoparticles or emulsions.
10. The pharmaceutical composition according to claim 9, characterized in that The carrier is solid lipid nanoparticles.
11. A method for preparing a polynucleotide according to claim 7, characterized in that: The method comprises the steps of: (1) preparing a DNA template; (2) performing an in vitro transcription reaction to obtain the polynucleotide according to claim 7, wherein the in vitro transcription reaction system contains RNA polymerase, nucleoside triphosphates and the capping analog according to any one of claims 1 to 6; The nucleoside triphosphate is selected from ATP, CTP, GTP, UTP, 5me-CTP, 5me-UTP, PseudoUTP or N1-me-PseudoUTP.
12. The preparation method according to claim 11, characterized in that: The RNA polymerase is derived from a bacteriophage.
13. The method according to claim 11 or 12, characterized in that The RNA polymerase is selected from T7, SP6, or T3.
